FY2024 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Equities researchers at Zacks Research cut their FY2024 earnings per share (EPS) estimates for shares of Bruker in a report released on Tuesday, November 26th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.40 per share for the year, down from their previous forecast of $2.60. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2024 earnings at $0.75 EPS, Q1 2025 earnings at $0.51 EPS, Q2 2025 earnings at $0.59 EPS, FY2025 earnings at $2.78 EPS, Q1 2026 earnings at $0.86 EPS, Q2 2026 earnings at $0.84 EPS, Q3 2026 earnings at $0.82 EPS and FY2026 earnings at $3.42 EPS.

Several other equities research analysts have also recently issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Citigroup lowered their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Barclays reduced their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Finally, TD Cowen lowered their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Trading Up 1.5 %

Bruker stock opened at $58.38 on Wednesday. The stock has a market cap of $8.85 billion, a PE ratio of 28.07, a P/E/G ratio of 3.95 and a beta of 1.20. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The stock has a 50-day moving average price of $61.02 and a 200 day moving average price of $64.24. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. During the same period in the previous year, the business posted $0.74 EPS. The business’s quarterly revenue was up 16.4% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC grew its stake in Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after purchasing an additional 2,521,904 shares in the last quarter. State Street Corp boosted its stake in shares of Bruker by 9.6% during the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after buying an additional 318,808 shares during the last quarter. RTW Investments LP grew its position in shares of Bruker by 1.1% during the third quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock worth $240,406,000 after buying an additional 37,024 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Bruker by 10.8% in the third quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock worth $137,702,000 after buying an additional 193,580 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Bruker by 127.8% in the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after acquiring an additional 779,549 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 28.30% of the company’s stock.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker’s dividend payout ratio is currently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.